Mylan set to introduce viable HIV treatments, Symfi Lo and Cimduo

Mylan set to introduce two new HIV treatments namely, Symfi Lo and Cimduo that was sanctioned in February by the U.S Food and Drug Administration. Introducing Symfi Lo in the coming weeks and Cimduo in the second quarter of this year. The upcoming launches will augment Mylan’s global  antiretroviral (ARV) platform and help redress the high cost of HIV treatment in the U.S.

Symfi Lo 400 mg/300 mg/300 mg tablets is a once-daily, single-tablet regimen and is heralded as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg. Cimduo (lamivudine and tenofovir disoproxil fumarate) 300 mg/300 mg tablets is a once-daily combination of two nucleo(t)side reverse transcriptase inhibitors and is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 35 kg.

Mylan CEO Heather Bresch said “For a decade, we have helped transform the level of access to high-quality, affordable HIV medications in developing countries. We are excited to bring that same passion to the U.S. with the upcoming launches of Symfi Lo and Cimduo and help deliver significant savings to the healthcare system.”

Lactic acidosis and hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including lamivudine and tenofovir disoproxil fumarate. Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus and HIV who have discontinued lamivudine and tenofovir disoproxil fumarate.